Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market is Expected to Grow at a CAGR of 23.6% in the Forecast Period of 2021-26

The “Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market,” is likely to grow at a CAGR of 23.6% in the forecast period of 2021-26, says MarkNtel Advisors in their research report “Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Analysis, 2021.” Artificial intelligence help accelerating the screening process and minimizing the time required for identifying drug molecule interactions and histology data. Therefore, the rising need to control drug discovery & development costs and reduce the overall time taken in this process propels the demand for Artificial Intelligence Enabled Drug Discovery and Clinical Trials, thereby boosting the market growth.

Further, increasing adoption of cloud-based applications & services and impending patent expiry of drugs are other crucial factors augmenting the growth of the Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market.

Key questions answered in the study

1. What are the current and future trends in the Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials market?
2. How has the industry been evolving in terms of geography and services adoption?
3. How has the competition been shaping across the globe, followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials market?
5. What are the customer orientation, purchase behavior, and expectations from the Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials market service providers?

Infectious Disease to Capture Significant Share of Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market During the Forecast Period

Based on the therapeutic Application, the market bifurcates into Oncology, Cardiovascular Disease, Nervous System Disease, Respiratory Disorder, Metabolic Disorder, Immunologic Disease, and Infectious Disease. Among these segments, Infectious Disease is likely to acquire substantial share of the Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market during the forecast period.

The adoption of AI by scientists helps them predict infectious diseases by understanding the behavior of microorganisms and curb their spread. It is further beneficial in faster drug discovery, thereby helps in gaining confidence to prevent & control the spread of these diseases.

“Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Analysis, 2021” provides comprehensive, qualitative, and quantitative insights on the market potential, key factors impacting the market growth, hotspots, and opportunities available for Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials providers across the globe. Moreover, the report also encompasses the key strategic imperatives for the competitors' success and strategic factorial indexing measuring competitor's capabilities on 16 parameters, which will help companies formulate 'Go to Market' strategies and identify the blue ocean for their offerings.    

Asia Pacific Region to Witness Significant Growth Rate During the Forecast Period

The Global Artificial Intelligence (AI) Enabled Drug Discovery & Clinical Trials Market is likely to acquire a significant share in the Asia Pacific region during the forecast period, primarily due to the fast adoption of advanced technologies like AI in the pharmaceutical industry and drug development process. In addition to this, beneficial government strategies & initiatives to integrate AI in the drug discovery and clinical trials methods shall propel the market growth in the coming years reveals, MarkNtel Advisors in their research report, “Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Analysis, 2021.”

According to MarkNtel Advisors, the leading industry players in the Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market are Accutar Biotechnology, Ardigen, Atomwise Inc., AiCure, LLC, Berg LLc, Cloud Pharmaceuticals, Biovista, Cyclica Inc., Symphony Innovations, and GNS Healthcare.

Market Segmentation:

1. By Component (Software, Service)
2. By Application (Data Aggregation and Analysis, Clinical Trials, Drug Design, Drug Characterization, Biomarker Research)
3. By Therapeutic Application (Oncology, Cardiovascular Disease, Nervous System Disease, Respiratory Disorder, Metabolic Disorder, Immunologic Disease, Infectious Disease)
4. By End-User (Biopharmaceutical Industry, Contract Research Organization (CROs), Academic Institutes and Research Centers)
5. By Geographic Region (North America, South America, Europe, Middle East & Africa, Asia Pacific)
6. By Countries (US, Canada, Mexico, Brazil, Argentina, Germany, France, Spain, Italy, UK, UAE, Saudi Arabia, China, India, Japan, Australia, South Korea)
7. By Competitors (Accutar Biotechnology, Ardigen, Atomwise Inc., AiCure, LLC, Berg LLc, Cloud Pharmaceuticals, Biovista, Cyclica Inc., Symphony Innovations, GNS Healthcare)